CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

HONG KONG, China and WILMINGTON, Del., Apr 1, 2024 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), and Incyte entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.

CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.

“We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Herve Hoppenot, Chief Executive Officer, Incyte. “There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.”

Mr. Huang Anjun, the general manager of CMS Skinhealth, stated that, “We expect that this collaboration will enhance CMS Skinhealth’s portfolio of potential treatments for vitiligo that, if approved, will provide differentiated treatment options for vitiligo patients in China. Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline ILUMETRI (tildrakizumab injection), original drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.”

The transaction is effective immediately upon the execution of the Collaboration and License Agreement.

About Povorcitinib

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Additionally, Phase 2 clinical studies of povorcitinib for PN, asthma and chronic spontaneous urticaria are also ongoing.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo.

It is estimated that there are approximately 14 million vitiligo patients in China and 6.5 million in the eleven Southeast Asian countries respectively. Non-segmental vitiligo patients account for approximately 85% of them[1]. Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 30[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo.

About Hidradenitis Suppurativa (HS)

HS is a chronic recurrent inflammatory skin condition characterized by the presence of painful inflammatory nodules, abscesses, ruptures, as well as the formation of sinus tracts and scarring. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS[3].

It is estimated that there are approximately 470 thousand HS patients in China, about 75% of whom are moderate to severe patients[4]. Additionally, it is estimated that there are approximately 13 thousand HS patients in the six Southeast Asian countries, comprising Thailand, Singapore, Malaysia, Philippine, Vietnam and Indonesia. HS has been included in the second batch of the Rare Disease List in China. Given the debilitating nature of condition, it can have a profoundly negative effect on patients’ quality of life. However, currently in China, there are no biologics or small molecule medicines approved by the National Medical Products Administration for the treatment of HS, creating an urgent need for effective therapeutic options[5].

About CMS Skinhealth

CMS’s Dermatology and Medical Aesthetic Business “CMS Skinhealth” regards dermatology prescription products as its core, and extends to dermatology-grade skincare products and light medical aesthetic products, continually optimizing full lifecycle skin-health management solutions, and gradually moving toward becoming “the largest and most professional skin-health management company in China “. Relying on its strong clinical development and commercialization advantages, CMS will realize the commercialization of povorcitinib in the Territory as soon as possible to meet the clinical needs of oral vitiligo drugs with efficacy and benefit relevant patients.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

Incyte Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether and when povorcitinib will be approved for use in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; whether and when CMS will bring povorcitinib to market in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; the potential of povorcitinib to treat patients with vitiligo, hidradenitis superativa or for any other indication; the potential for Incyte to receive royalties and payments from CMS for development and commercial milestones; and the potential for Incyte to broaden its ability to bring new medicines to patients in Asia and elsewhere, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; Incyte’s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte’s products and the products of its collaboration partners; the acceptance of Incyte’s products and the products of its collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended December 31, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements.

CMS Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. This press release may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from this press release is expressly excluded.

Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Group assumes no obligation to update any forward-looking information contained in this press release. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Contacts:
CMS
Investor Relations: ir@cms.net.cn

Incyte
Media: media@incyte.com
Investors: ir@incyte.com

Reference

1. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15. PMID: 25596811

2. Frisoli M, et al. Vitiligo: mechanisms of pathogenesis and treatment. Annu. Rev. Immunol. 2020;38(1):621-648

3. Solimani, F., Meier, K., & Ghoreschi, K. (2019). Emerging topical and systemic JAK inhibitors in dermatology. Frontiers in immunology, 10, 2847

4. Prevalence of Acne Inversa (Hidradenitis Suppurativa) in China: A Nationwide Cross-Sectional Epidemiological Study

5. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement (2021 version)

Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Website: https://web.cms.net.cn/en/home/

Odyne and FCCC Announce Agreement March 2024

 Odyne Systems, LLC and Freightliner Custom Chassis Corp. Announce Agreement

Odyne Systems, LLC, a provider of electrification technologies for medium and heavy-duty vehicles, and Freightliner Custom Chassis Corp. (FCCC) are pleased to announce that Odyne is now able to offer their zero-emissions export power systems directly through FCCC dealers for use on the FCCC MT50e all-electric commercial chassis. The export power system will be installed by Odyne or a Freightliner Dealer before the final body installation to minimize end-customer delivery time.

The Odyne export power system, referred to as Odyne evAPU (electric vehicle Auxiliary Power Unit), will eliminate the need for fossil fuel powered generators on the MT50e chassis used in work truck applications. Thousands of work vehicles use generators to provide electrical power for tools and equipment at job sites, creating unnecessary harmful emissions and noise pollution. The Odyne evAPU system has a large 35 kWh grid-recharged battery system and export power inverters that provide 6 to 12 kW of AC 120V or 240V electrical power.

Designed for the rugged environment encountered by work trucks, the Odyne evAPU is mounted within the FCCC frame, freeing up space in the truck body that would typically be required for a diesel or gasoline generator. The evAPU utilizes IP67 components and is thermally managed to provide for operations in harsh conditions over a broad temperature range.

Joe Dalum, CEO of Odyne Systems, LLC, commented, “Odyne is excited to partner with Freightliner Custom Chassis Corp (FCCC) to deliver innovative zero-emissions export power systems. Thousands of work vehicles contribute to unnecessary emissions and noise pollution through generators. Odyne looks forward to providing the all-electric Odyne evAPU, which replaces traditional generators on work trucks, through FCCC dealers nationwide.”

Odyne will be displaying the new evAPU system at the NTEA Work Truck Week in Indianapolis from March 5-8.

About Odyne Systems, LLC
Odyne is a leader in the electrification of medium and heavy-duty vehicles. Odyne’s advanced plug-in technology enables trucks over 14,000 pounds to have substantially lower fuel consumption, lower emissions, improved performance, quieter job site operation, and reduced operating and maintenance costs. Odyne’s zero-emissions evAPU systems eliminate the need for generators, and its ePTO and hybrid systems are approved to operate with transmissions from Allison Transmission and are sold directly to vehicle manufacturers or to fleets. Odyne has authorized selected Allison Transmission distributors to service Odyne systems across North America. For further information, visit www.odyne.com.

About Freightliner Custom Chassis Corporation (FCCC)
Freightliner Custom Chassis Corp. (FCCC) is a leading manufacturer of gas, diesel and alternative-fuel chassis for the medium-duty pick-up and delivery markets. FCCC supports its industry-leading chassis with a comprehensive suite of services, including 24/7 factory direct support, a nationwide service network with more than 400 dealers in the U.S. and Canada, and an official customer-support mobile app. FCCC also manufactures chassis for the motor home, school bus and shuttle bus markets. Freightliner Custom Chassis Corporation is a subsidiary of Daimler Trucks North America LLC, a Daimler company. For more information, visit fccccommercial.com or call 1-800-FTL-HELP.

Odyne Systems, LLC
Leonard Lincoln
(262) 336-5712
www.odyne.com/
Follow us on Twitter, Facebook & Instagram @OdyneSystems

ContactContact

Categories

  • Alternative Energy
  • Business
  • Engineering
  • Government
  • Green Products & Services
  • Industrial Technology
  • Off-Road Trucks & SUVs
  • Technology
  • Trucking
  • Utilities

Dow and Evonik announce the successful startup and operation of hydrogen peroxide to propylene glycol (HPPG) pilot plant

Innovative technology powered by a flexible business model to better address future customer demand

HORGEN, Switzerland, and HANAU, Germany – WEBWIRE

Dow (NYSE: DOW) and Evonik are proud to announce the successful start-up and operation of a pioneering hydrogen peroxide to propylene glycol (HPPG) pilot plant at Evoniks site in Hanau, Germany. Collaboratively developed by Dow, the worlds largest producer of propylene glycol, and globally leading hydrogen peroxide manufacturer Evonik, the plant uses the distinct HYPROSYN method to enable the direct synthesis of propylene glycol (PG) from hydrogen peroxide and propylene.

At Dow, we believe in collaborating with our customers and other stakeholders to create, innovate and find solutions to big challenges. So, I am delighted to see this plant become operational through this collaboration, said Andrew Jones, global business director for Chlor-Alkali Vinyl & Propylene Oxide, Propylene Glycol, at Dow. With this innovative technology and flexible asset and business model, we are well positioned to meet our customers needs and growing market demand.

At Evonik Active Oxygens, we put sustainability at the core of futurizing our business. This relies not only on innovative technologies, but also the ability to scale these up and bring them to market, remarked Michael Trxler, head of Evoniks Active Oxygens business line. Thats where excellent strategic partnerships come into play. The startup of this pilot plant in Hanau thus not only represents a major technological milestone in our efforts to make
industry more sustainable, it is also a prime example of how cross-company collaboration, like this partnership with Dow, is essential to driving sustainable solutions.

The pilot plant will demonstrate the benefits of the novel technology. In contrast to the traditional process, where propylene is used to make propylene oxide (PO), which is converted to PG through hydrolysis, the HYPROSYN process uses a novel catalytic system to generate PG directly from propylene and hydrogen peroxide. The integration of all key reaction stages in a single reactor eliminates the need of additional investments in PO capacity and lowers capital requirements. The process also enables a reduced environmental footprint e.g., water consumption is reduced to less than 5% compared to conventional PG methods. In addition, existing PG plants can be retrofitted to benefit from
this new technology.

Propylene glycol serves as an essential ingredient such as a high-performing additive, intermediate, or initiator in a wide range of applications including industrial, food and animal feed, pharmaceuticals, and cosmetics. Over the next few years, the Dow and Evonik teams will continuously evaluate the plants operations and capabilities to scale up manufacturing, in support of growing market demand.

For more information please visit:Dow propylene glycol solutionsandevonik.click/hyprosyn

About Evonik
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of 18.5 billion and an operating profit (adjusted EBITDA) of 2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow. For more information, please visit evonik.com.

About Dow
Dow (NYSE: DOW) combines global breadth; asset integration and scale; focused innovation and materials science expertise; leading business positions; and environmental, social and governance leadership to achieve profitable growth and help deliver a sustainable future. The Companys ambition
is to become the most innovative, customer centric, inclusive and sustainable materials science company in the world. Dows portfolio of plastics, industrial intermediates, coatings and silicones businesses delivers a broad range of differentiated, science-based products and solutions for its customers in high-growth market segments, such as packaging, infrastructure, mobility and consumer applications. Dow operates manufacturing sites in 31 countries and employs approximately 37,800 people. Dow delivered sales of approximately $57 billion in 2022. References to Dow or the Company mean Dow Inc. and its subsidiaries. For more information, please visitwww.dow.com

1PointFive and TD Announce One of the Finance Industry’s Largest Purchases of Direct Air Capture Carbon Removal Credits

HOUSTON and TORONTO – WEBWIRE

1PointFive, a carbon capture, utilization and sequestration company, and TD Bank Group (TD), today announced a purchase of carbon dioxide removal (CDR) credits from STRATOS 1PointFives first Direct Air Capture (DAC) plant currently under construction in Texas.

Under the terms of the agreement, and subject to STRATOS becoming operational, TD Securities has agreed to purchase 27,500 metric tons of DAC CDR credits over four years. This represents one of the largest purchases of DAC CDR credits by a financial institution and demonstrates TDs continuing strategic focus on energy transition.

STRATOS has been designed to be the first large scale commercial deployment of DAC technology globally, with the potential to capture and remove up to 500,000 metric tons of CO2from the atmosphere each year for secure and long-term storage in geologic formations. 1PointFives CDR credits are expected to provide a practical and high integrity solution for organizations to address their emissions.

With this transaction, TD Securities expects to add to its portfolio of voluntary carbon offsets, as it continues to build out its carbon advisory and trading capabilities in the voluntary and compliance carbon markets. These capabilities complement TD Securities broader ESG Solutions platform, with a focus on providing clients with short, medium and long-term solutions as they transition to a lower carbon economy. In addition, TD intends to use a portion of the credits from this transaction to offset its own operational emissions.

As the need to move from climate commitments to action intensifies, corporations across all sectors are looking for tangible ways to achieve their net zero goals, said Amy West, Global Head ESG Solutions, TD Securities. Were incredibly proud to partner with 1PointFive to support innovative, technology-based solutions that are intended to advance both our clients and our own decarbonization goals.

1PointFive is progressing the development of Carbon Engineerings Direct Air Capture technology, alongside other decarbonization solutions, at an industrial scale to help organizations achieve their net-zero goals. Under the agreement with TD Securities, the captured CO2underlying the removal credits will be stored through geologic sequestration and not through an enhanced oil recovery process.

We are proud to partner with TD Securities and believe their purchase demonstrates how Direct Air Capture can become a vital tool in an organizations sustainability strategy and help further net-zero goals, said Michael Avery, President and General Manager, 1PointFive. Carbon removal credits from Direct Air Capture will be measurable, transparent and durable, with the goal of providing a solution for organizations to address their emissions.

The transition to a low-carbon economy is complex, and relies on transformative action across sectors and economies, including the adoption of new technologies, said Janice Farrell Jones, SVP, Sustainability and Corporate Citizenship, TD. Direct Air Capture holds enormous promise as a tool to drive progress on this journey and we are proud to play a role, helping to scale innovation and support this growing business opportunity”

In 2020, TD announced an ambitious Climate Action Plan to target net-zero greenhouse gas emissions associated with its operating and financing activities by 2050.
TDs carbon markets and sustainable finance activities include the following:

  • TD has been listed on the Dow Jones Sustainability World Index for nine consecutive years and is currently the top-ranked North American-based bank on the World Index
  • TD Securities is an active member of the International Emissions Trading Association (IETA)
  • TD Securities established a Carbon Markets Advisory team, focused on the compliance and voluntary markets
  • TD Securities invested $10 million in the Boreal Wildlands Carbon Project, the largest private land conservation effort in Canadian history
  • In 2022, TD Securities joined Rubicon Carbons coalition of corporate sustainability lenders to help bring greater scale, confidence and innovation across all facets of the carbon market.
  • Earlier this year, TD announced a newSustainable & Decarbonization Finance Targetthat aims to mobilize$500 billionCAD by 2030 through financial activities including lending, financing, underwriting, advisory services, insurance, and TDs own investments.

About 1PointFive

1PointFive is a Carbon Capture, Utilization and Sequestration (CCUS) company that is working to help curb global temperature rise to 1.5C by 2050 through the deployment of decarbonization solutions, including Carbon Engineerings Direct Air Capture (DAC) and AIR TO FUELS technologies alongside geologic sequestration hubs. Visitwww.1PointFive.comfor more information.

AIR TO FUELS is a registered trademark of Carbon Engineering Ltd.

About TD Bank Group

The Toronto-Dominion Bank and its subsidiaries are collectively known as TD Bank Group (TD or the Bank). TD is the sixth largest bank in North America by assets and serves over 27.5 million customers in four key businesses operating in a number of locations in financial centres around the globe: Canadian Personal and Commercial Banking, including TD Canada Trust and TD Auto Finance Canada; U.S. Retail, including TD Bank, Americas Most Convenient Bank, TD Auto Finance U.S., TD Wealth (U.S.), and an investment in The Charles Schwab Corporation; Wealth Management and Insurance, including TD Wealth (Canada), TD Direct Investing, and TD Insurance; and Wholesale Banking, including TD Securities and TD Cowen. TD also ranks among the worlds leading online financial services firms, with more than 16 million active online and mobile customers. TD had $1.9 trillion in assets on July 31, 2023. The Toronto-Dominion Bank trades under the symbol TD on the Toronto and New York Stock Exchanges.

Forward-Looking Statements

1PointFive

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those relating to the agreements benefits and related impact on carbon emissions and Occidentals (NYSE: OXY) and its subsidiaries deployment and use of DAC technology, which are based on Occidentals current expectations, beliefs, plans, estimates, and forecasts. All statements other than statements of historical fact are forward-looking statements for purposes of federal and state securities laws. Words such as believe, will, may, expect, plan, or similar expressions that convey the prospective nature of events or outcomes are generally indicative of forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. Unless legally required, Occidental does not undertake any obligation to update, modify, or withdraw any forward-looking statements as a result of new information, future events, or otherwise.

These statements are not guarantees of future performance as they involve assumptions that may prove to be incorrect and risks and uncertainties, including those that are beyond Occidentals control. Factors that may cause actual results to differ materially from forward-looking statements include Occidentals and its subsidiaries ability to access necessary technology, to develop and employ existing or new technology on a commercial scale, to access capital, to collaborate with third parties and customers, and to receive approvals from regulatory bodies, as well as market conditions, geopolitical events, and scientific developments. Additional factors that may affect Occidentals and its subsidiaries ability to deploy DAC technology can be found in Occidentals filings with the U.S. Securities and Exchange Commission (SEC), which may be accessed at Occidentals website at oxy.com or the SECs website at sec.gov. Information included herein is not necessarily material to an investor in Occidentals securities.

TD

From time to time, The Toronto-Dominion Bank (TD or the Bank) makes written and/or oral forward-looking statements, including in this document, in other filings with Canadian regulators or the United States (U.S.) Securities and Exchange Commission (SEC), and in other communications. In addition, representatives of the Bank may make forward-looking statements orally to analysts, investors, the media and others. All such statements are made pursuant to the safe harbour provisions of, and are intended to be forward-looking statements under, applicable Canadian and U.S. securities legislation, including the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements made in this document regarding the Banks financial performance objectives, vision and strategic goals and the Banks social, economic, environmental and governance- related impacts and objectives, including the Banks greenhouse gas (GHG) emission reduction targets and the Banks Sustainable & Decarbonization Finance Target. Forward-looking statements are typically identified by words such as will, would, should, believe, expect, anticipate, intend, estimate, plan, goal, target, may, and could.

By their very nature, these forward-looking statements require the Bank to make assumptions and are subject to inherent risks and uncertainties, general and specific. Especially in light of the uncertainty related to the physical, financial, economic, political, and regulatory environments, such risks and uncertainties many of which are beyond the Banks control and the effects of which can be difficult to predict may cause actual results to differ materially from the expectations expressed in the forward-looking statements. Risk factors that could cause, individually or in the aggregate, such differences include: strategic, credit, market (including equity, commodity, foreign exchange, interest rate, and credit spreads), operational (including technology, cyber security, and infrastructure), model, insurance, liquidity, capital adequacy, legal, regulatory compliance and conduct, reputational, environmental and social, and other risks. Examples of such risk factors include general business and economic conditions in the regions in which the Bank operates; geopolitical risk; inflation, rising rates and recession; the economic, financial, and other impacts of pandemics, including the COVID-19 pandemic; the ability of the Bank to execute on long-term strategies and shorter-term key strategic priorities, including the successful completion and integration of acquisitions and dispositions, business retention plans, and strategic plans; technology and cyber security risk (including cyber-attacks, data security breaches or technology failures) on the Banks information technology, internet, network access or other voice or data communications systems or services; model risk; fraud activity; the failure of third parties to comply with their obligations to the Bank or its affiliates, including relating to the care and control of information, and other risks arising from the Banks use of third-party service providers; the impact of new and changes to, or application of, current laws and regulations, including without limitation tax laws, capital guidelines and liquidity regulatory guidance; regulatory oversight and compliance risk; increased competition from incumbents and new entrants (including Fintechs and big technology competitors); shifts in consumer attitudes and disruptive technology; exposure related to significant litigation and regulatory matters; ability of the Bank to attract, develop, and retain key talent; changes to the Banks credit ratings; changes in foreign exchange rates, interest rates, credit spreads and equity prices; increased funding costs and market volatility due to market illiquidity and competition for funding; Interbank Offered Rate (IBOR) transition risk; critical accounting estimates and changes to accounting standards, policies, and methods used by the Bank; existing and potential international debt crises; environmental and social risk (including climate change); and the occurrence of natural and unnatural catastrophic events and claims resulting from such events. In addition, information on the assumptions, risks, uncertainties and other factors affecting the Banks GHG emissions targets and the Banks Sustainable & Decarbonization Finance Target may be found here:Cautionary Statement Regarding Disclosure on Emission TargetsandCautionary Statement Regarding Disclosure on Sustainable & Decarbonization Finance Target

The Bank cautions that the preceding list is not exhaustive of all possible risk factors and other factors could also adversely affect the Banks results. For more detailed information, please refer to the Risk Factors and Management section of the 2022 MD&A, as may be updated in subsequently filed quarterly reports to shareholders and news releases (as applicable) related to any events or transactions discussed under the heading Significant Acquisitions or Significant and Subsequent Events, and Pending Acquisitions in the relevant MD&A, which applicable releases may be found onwww.td.com. All such factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements, should be considered carefully when making decisions with respect to the Bank. The Bank cautions readers not to place undue reliance on the Banks forward-looking statements.

Material economic assumptions underlying the forward-looking statements contained in this document are set out in the 2022 MD&A under the heading Economic Summary and Outlook, under the headings Key Priorities for 2023 and Operating Environment and Outlook for the Canadian Personal and Commercial Banking, U.S. Retail, Wealth Management and Insurance, and Wholesale Banking segments, and under the heading 2022 Accomplishments and Focus for 2023 for the Corporate segment, each as may be updated in subsequently filed quarterly reports to shareholders.

Any forward-looking statements contained in this document represent the views of management only as of the date hereof and are presented for the purpose of assisting the Banks shareholders and analysts in understanding the Banks financial position, objectives and priorities and anticipated financial performance as at and for the periods ended on the dates presented and may not be appropriate for other purposes. The Bank does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation.

Any references to sustainable investing, sustainable finance, ESG,, carbon neutral, net-zero or similar terms in this document are intended as references to the internally defined criteria of the Bank and not to any jurisdiction-specific regulatory definition that may exist.

View the full releasehere.

ACEC/MA Announce Bronze Excellence Award Winners for 2023

Nominations open for 2023 Engineering Excellence Awards through October 3rd.

Nitsch Engineering Gardner Street Roadway

Nitsch Engineering Gardner Street Roadway

BOSTONSept. 1, 2023PRLog — The Engineering Excellence Awards are an annual celebration of engineering excellence, honoring projects worldwide that demonstrate innovation, creative problem-solving, and engineering’s unique ability to improve our world. The competition provides visibility for the firm, the design team, the client and the project. The top winners at the state level proceed to the national competition administered by the American Council of Engineering Companies in Washington, DC, where they will compete for, among other awards, the coveted national Grand Conceptor Award. For more information about entering the competition and to download the entry form: https://www.acecma.org/about/news/2024-engineering-excellence-awards-competition-5051

2023 Bronze ACEC/MA Engineering Excellence Award winners:

  • Arup US, Inc. for the Brookville Electric Vehicle Bus Depot serving Montgomery County Maryland.  
  • Arup US., Inc for the Massachusetts Institute of Technology (MIT) Graduate Tower at Site 4.
  • Beals and Thomas for The Country Club Pond Dredging and U.S. Open Preparations.
  • CDR Maguire, Inc. for the West Oxbow Road over Wilder Brook Bridge Replacement Projects.
  • Dewberry for the Bridge Replacement of Evergreen Road over Mason Brook for client MassDOT.
  • Dewberry for the City-wide Sewer Separation Master Plan for the City of Chelsea.
  • Environmental Partners Group for Elevating Resilience; Town of Lexington Leverages Green Infrastructure for Stormwater Solutions.
  • Fitzemeyer & Tocci Associates, Inc. for the engineering and construction administration for the fast paced design and construction of BAE Systems Manchester – Engineering & Production Facility.
  • Fitzemeyer & Tocci Associates, Inc. for Worcester Polytechnic Institute’s Kaven Hall.
  • Gannett Fleming provided engineering design services to replace the existing Umpachene Falls Road over Konkapot River Bridge in the Town of New Marlborough.
  • Jacobs Engineering Group, Inc. with client MassDOT reconstructed the failed railroad embankment and restored rail service to the Cape Main Line MP 67.0 in 27 days.
  • Jacobs Engineering Group Inc. Implementation of the Hyannis Master Plan.
  • Jacobs Engineering Group, Inc working with Engleberth Construction, Inc. on the Terminal Integration Project for Burlington International Airport.
  • Nitsch Engineering for the Gardner Street Roadway Reconstruction Project.
  • Nitsch Engineering’s Stormwater Improvement Project for Tufts University.
  • TranSystems working with MassDOT and the City of Fall River prepared preliminary design for a drastic transformation of the Taunton River Waterfront with Route 79/Davol Street Improvements.
  • VHB working with MassDOT completed the Spy Pond Dredge and Stormwater Improvements project which consisted of a feasibility study and subsequent design and permitting to dredge 625 cubic yards of contaminated sediment and upgrade the drainage system that discharges to Spy Pond, which ultimately restored recreational access to the pond.
  • Waterfield Design Group, Inc. was recognized for the Boon Street Presbyterian Church Reconstruction and Adaptive Reuse project.
  • Woodard & Curran was retained by the Town of Mansfield to design the Cate Spring Well PFAS Treatment System.

For more information on ACEC/MA, visit their website at www.acecma.org